Centiva Capital LP Acquires 3,338 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Centiva Capital LP grew its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 51.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 9,803 shares of the company’s stock after buying an additional 3,338 shares during the quarter. Centiva Capital LP’s holdings in Amphastar Pharmaceuticals were worth $364,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of AMPH. Brevan Howard Capital Management LP purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter worth approximately $256,000. Ameriprise Financial Inc. lifted its stake in Amphastar Pharmaceuticals by 1.0% in the 4th quarter. Ameriprise Financial Inc. now owns 146,015 shares of the company’s stock worth $5,422,000 after purchasing an additional 1,417 shares in the last quarter. Aristeia Capital L.L.C. purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter worth approximately $1,605,000. Jane Street Group LLC lifted its stake in Amphastar Pharmaceuticals by 23.0% in the 4th quarter. Jane Street Group LLC now owns 99,487 shares of the company’s stock worth $3,694,000 after purchasing an additional 18,573 shares in the last quarter. Finally, PDT Partners LLC lifted its stake in Amphastar Pharmaceuticals by 11.5% in the 4th quarter. PDT Partners LLC now owns 90,484 shares of the company’s stock worth $3,360,000 after purchasing an additional 9,300 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on AMPH shares. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Friday, March 21st. Finally, Wells Fargo & Company decreased their price target on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday.

Amphastar Pharmaceuticals Trading Down 2.2%

Shares of AMPH opened at $24.11 on Monday. The stock has a market capitalization of $1.15 billion, a P/E ratio of 8.04, a PEG ratio of 2.19 and a beta of 0.78. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a fifty day simple moving average of $25.83 and a two-hundred day simple moving average of $34.66. Amphastar Pharmaceuticals, Inc. has a twelve month low of $22.64 and a twelve month high of $53.96.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company’s stock, valued at $2,681,377.02. This represents a 4.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 5,231 shares of company stock valued at $142,752 in the last quarter. Company insiders own 27.50% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.